

Biomaterials, Medical Devices, and Combination Products

Biocompatibility Testing and
Safety Assessment



Shayne Cox Gad
Samantha Gad-McDonald



CRC Press
Taylor & Francis Group

Biomaterials, Medical Devices, and Combination Products


Biocompatibility Testing and Safety Assessment

Shayne Cox Gad

Gad Consulting Services
Cary, North Carolina, USA

Samantha Gad-McDonald

Gad Consulting Services
Cary, North Carolina, USA



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2016 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper
Version Date: 20151020

International Standard Book Number-13: 978-1-4822-4837-1 (Hardback)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Printed and bound by CPI Group (UK) Ltd, Croydon, CR0 4YY

Biomaterials, Medical Devices, and Combination Products

**Biocompatibility Testing and
Safety Assessment**

Preface

Biomaterials, Medical Devices, and Combination Products: Biocompatibility Testing and Safety Assessment constitutes a completely revised and much expanded version of the third edition of *Safety Evaluation in the Development of Medical Devices Combination Products*. While continuing to focus on the objective of the earlier editions (to serve as a single-volume utilitarian guide for those who are responsible for or concerned with developing and ensuring patient safety in the use and manufacture of medical devices, it also reflects the vast changes that have come to pass in the 7 years since the third edition was published. It not only updates throughout, but also adds two new chapters: 16, Special Case Devices, and 19, Leachables and Extractables, which incorporates coverage of current analytical methods (authored in part by Dr. Dave Albert) and the use of quantitative structure–activity relationship methodology as a tool for use in supplementing actual testing.

Foremost, this new edition has been recast throughout to address the fact that device markets are global, that technology continues to advance, and that global device safety regulation has been increasingly harmonized. Each aspect of device safety evaluation is considered in terms of International Organization for Standardization (ISO), U.S. Food and Drug Administration (FDA), European Union (EU), and Japanese Ministry of Health, Labour, and Welfare (MHLW) perspectives. Additionally, the continuing growth of technology has led to the incorporation of science (particularly in the areas of immunotoxicology and toxicokinetics). Also incorporated are new case examples and citations with the means of access to Internet-based regulatory and scientific sites, reflecting the universal adoption of this technology into our world.

Authors

Shayne C. Gad earned a BS in chemistry and biology from Whittier College, California, in 1970, and after active-duty service in the U.S. Navy, earned a PhD in Pharmacology/Toxicology (Texas, 1977) DABT. He is currently Principal of Gad Consulting Services, a 23-year-old consulting firm with 7 employees and more than 500 clients (in the pharmaceutical and device industries). He is past president of the American College of Toxicology, the Roundtable of Toxicology Consultants, and three of the Society of Toxicology's specialty sections, and recipient of the American College of Toxicology Lifetime Contribution Award in 2008. He served on council, membership, program, and research committees for the American College of Toxicology, and previously at Carnegie Mellon Institute of Research (CMIR) Chemical Hygiene Fellowship, Allied Chemical, Searle, Becton Dickinson, and Synergen. He has authored or edited 47 published books and more than 350 chapters, articles, and abstracts in the fields of toxicology, statistics, pharmacology, drug and device development, and safety assessment. He has more than 37 years of broad-based experience in toxicology, drug and device development, statistics, and risk assessment, and has specific expertise in neurotoxicology, *in vitro* methods, cardiovascular toxicology, inhalation toxicology, immunotoxicology, risk assessment, and genotoxicology. Dr. Gad has served as a grant reviewer for the U.S. Environmental Protection Agency, Center for Alternatives to Animal Testing (CAAT), the National Institutes of Health, and Canadian Health. He has direct involvement in the preparation of investigational new drugs (107 successfully to date), new drug applications, Product Listing Approvals (PLA), Abbreviated New Drug Approvals (ANDA), 510(k), investigational device exemption, Common Technical Document (CTD), clinical databases for phase 1 and 2 studies, and premarket approvals. Dr. Gad has also served as the chief operating officer of two pharmaceutical companies while a consultant. He initiated and has conducted the triennial toxicology salary survey as a service to the profession of toxicology for the last 25 years.

Samantha Gad-McDonald earned her BS in chemical engineering from the University of Cincinnati in 2004. She began her career as a production leader in good manufacturing process manufacturing facilities. During this time, she helped design processing systems and procedures, and validated equipment for a new good manufacturing process processing facility.

Samantha joined Gad Consulting Services (GCS) permanently in 2009, where she is a staff chemical engineer and consulting associate. For companies large and small, she has assessed the biocompatibility of medical devices, compiled and maintained investigational new drug applications, conducted audits, and maintained drug master files. She has familiarized herself with the regulation and guidelines of the U.S. Food and Drug Administration, the International Conference on Harmonization, and other international regulatory agencies necessary to evaluate the safety of chemical compounds. She has published 1 paper and contributed 40 entries to the *Encyclopedia of Toxicology*, as well as having two poster presentations and being an invited speaker of the FDA. Finally, she is proud to have passed her knowledge on by teaching several courses on drug development, medical device safety evaluation, and risk assessment methods, alongside giving presentations for professional meetings such as for the American College of Toxicology and for corporate clients.

Contents

Preface.....	xix
Authors.....	xxi
 Chapter 1 Safety Evaluation of Medical Devices	1
Introduction	1
Biocompatibility	1
Fundamentals of Biocompatibility Tests	2
Scope of Devices and the Medical Device Market.....	4
History	5
Nonspecific Regulatory Considerations	6
Good Laboratory Practices	6
Animal Welfare Act (AWA).....	7
Regulations versus Law	7
Organizations Regulating Drug and Device Safety in the United States	7
References	8
 Chapter 2 Regulatory Aspects and Strategy in Medical Device and Biomaterials	11
Safety Evaluation.....	11
Regulatory Basis.....	11
Regulations: General Considerations for United States	11
Regulations versus Law	13
Organizations Regulating Device Safety in the United States	13
Classification of Devices	14
Toxicity Testing: Medical Devices	20
Device Categories: Definitions and Examples	23
Biological Tests	24
United States Pharmacopeial Testing	29
ISO Testing Requirements.....	30
MHLW Requirements.....	31
CE Marking of Devices	32
Risk Assessment	37
Standards and Guidances.....	37
Method.....	38
Hazard Identification	38
Dose–Response Assessment.....	38
Exposure Assessment	38
Risk Characterization	38
Case Studies.....	38
Nitinol Implant	38
Wound Dressings.....	39
Perchloroethylene Solvent.....	40
Ligature Material	40

Sources of Data.....	41
Uncertainty Factors.....	41
Safety Margins.....	42
References	42
Chapter 3 Road Map to Test Selections	45
Key Concepts.....	45
Condition of Use.....	45
Materials, Components, and Products	46
Chemical and Physical Property Considerations.....	46
Residual Monomers.....	49
Residual Solvents	49
Degradation Products	49
By-Products from Irradiation	49
Sterilization Residuals.....	49
Formulation Additives	50
Inadvertent Contaminants.....	50
Bacterial Endotoxins	50
Specific Material Considerations.....	50
Physical Properties of Polymers, Elastomers, and Silicones.....	55
Biologically Derived Materials	56
Factors Influencing Test Selection.....	57
Perceptions	57
Hazard Identification	57
Risk Assessment.....	58
Claims.....	58
Time and Economies	58
Prior Knowledge.....	58
Miscellaneous Reference Sources.....	60
Search Procedure.....	62
Monitoring Published Literature and Other Research in Progress.....	62
New Sources.....	63
Kinds of Available Information (Always Changing, Ever Faster, in the Digital Age)	63
PC-Based Information Products: Laser Disc.....	65
Types and Uses of Tests.....	65
Reasonable Man	65
Qualifications versus Process Control	66
Tiers of Concern: Consumers, Health-Care Providers, and Manufacturing Employees	66
Sterilization and Cleanliness	68
References	69
Chapter 4 Materials in Medical Device Design.....	73
Introduction	73
Metals	74
Stainless Steel.....	74
Nitinol.....	76

	Bioactive Metals	76
	Magnesium	76
	Tantalum	77
	Other Metals	77
	Ceramics and Glasses	77
	Polymers	78
	Elastomers	85
	Silicones	88
	Shape Memory Polymers	89
	Hydrogels	89
	Textiles	89
	Fibers	89
	Biologically Sourced Materials	90
	Colorants	90
	Surface-Modifying Materials	95
	Tissue Engineering Scaffolds	95
	Nanomaterials	96
	Organic	96
	Inorganic	97
	Quantum Dots	97
	Dendrimers	97
	References	97
Chapter 5	What to Test: Sampling and Sample Preparation	101
	Sampling	101
	Randomization	102
	Sample Preparation	103
	Procedure	107
	Reference Materials	108
	Conclusion	108
	References	109
Chapter 6	Cytotoxicity Testing	111
	Introduction	111
	Background	111
	Crystal Violet Staining	114
	Silicone Microphysiometer	114
	Microtox Test	114
	Neutral Red Uptake (NRU) Assay	114
	MTT	114
	Agar Diffusion Test	117
	Direct Contact Test	118
	Elution Test	118
	Colony-Forming Assay (CFA)	119
	Correlation with <i>In Vivo</i> Results	119
	Conclusion	119
	References	120

Chapter 7	Hemocompatibility (ISO 10993-4)	123
	Noncontact Devices	125
	External Communicating Devices	125
	Implant Devices	126
	Standard Tests	127
	Hemolysis Tests	128
	The Osmotic Fragility Test	131
	Erythrocyte Stability	132
	Whole Blood Clotting Time	132
	Thrombogenicity	133
	Complement Activation	134
	Protein Adsorption	134
	Coagulation	134
	Platelets	135
	Conclusion	136
	References	136
Chapter 8	Local Tissue Tolerance	139
	Dermal Irritation	139
	Primary Dermal Irritation Test	141
	<i>In Vitro</i> Alternatives	143
	Ocular Irritation Testing	143
	Primary Eye Irritation Test	145
	Alternatives	146
	Other Nonparenteral Route Irritation Tests	148
	Parenteral Irritation/Tolerance	150
	Parenteral Routes	150
	Test Systems for Parenteral Irritation	151
	Acute Intramuscular Irritation in the Male Rabbit	151
	Acute Intravenous Irritation in the Male Rabbit	152
	Alternatives	154
	Intracutaneous Irritation	154
	Intracutaneous Test	154
	Pyrogenicity	155
	Reference Standard and Control Standard Endotoxins	156
	Preparatory Testing	157
	Inhibition or Enhancement Test	157
	Test Procedure	158
	Preparation	158
	Maximum Valid Dilution	159
	Calculation and Interpretation	159
	Interpretation	159
	Rabbit Pyrogen Test	160
	Factors Affecting Irritation Responses and Test Outcome	161
	References	162
Chapter 9	Immunotoxicology (ISO 10993-20)	167
	Overview of the Immune System	168
	Immunotoxic Effects	172

Immunosuppression	172
Immunostimulation	174
Hypersensitivity	175
Autoimmunity	178
Evaluation of the Immune System	180
Regulatory Positions	180
The CDRH Testing Framework	184
Immunopathologic Assessments	184
Humoral Immunity	187
Cell-Mediated Immunity	188
Nonspecific Immunity	190
Host-Resistance Assays	191
Hypersensitivity	192
Objectives and General Features	194
History	195
Modified Buehler Procedure	196
Guinea Pig Maximization Test	200
Mouse Ear Swelling Test (MEST)	205
Local Lymph Node Assay (LLNA)	210
Approaches	213
Suggested Approaches to Testing	213
Suggested Approaches to Evaluation of Results	213
Problems and Future Directions	215
References	216

Chapter 10 Implantation Biology and Studies	223
USP Implantation Test	223
British Pharmacopoeia	225
ISO 10993 Implantation Test	225
Preparation of Specimens for Implantation	226
Solid Specimens (Excluding Powders)	226
Nonsolid Specimens (Including Powders)	226
Control Specimens	226
Animals and Tissues	226
Test Periods	227
Surgery	228
Postoperative Assessment	228
Euthanasia	228
Evaluation of Biological Response	228
Macroscopic Assessment	228
Preparation for Histology: Implant Retrieval and Specimen Preparation	228
Histological Assessment	229
Implant Specimens	229
Animals and Implantation	229
Retrieval and Histological Procedure	229
Evaluation	229
Test Method for Implantation in Subcutaneous Tissue	230
Field of Application	230
Principle	230
Test Specimens	230

Test Animals and Implant Sites	230
Implantation Procedure	230
Implantation along Dorsal Midline	230
Implantation in Neck	230
Implantation Period	231
Evaluation of Biological Response	231
Test Method for Implantation in Muscle	231
Test Method for Implantation in Bone	232
Control Materials	233
Long-Term Implant Studies	233
Number of Test and Control Implants	236
Conditioning	237
Implantation Period	237
Postoperative Care	237
Sacrifice and Implant Retrieval	237
Postmortem Observations	238
Histological Procedure	238
Tissue Sample Preparation	238
Histopathological Observations	238
Report	239
Granulomatous Inflammation	240
Considerations	240
References	241
 Chapter 11 Acute Systemic Toxicity Testing and Device Safety Evaluation.....	243
Introduction	243
Acute Systemic Toxicity Characterization	243
Clinical Signs.....	245
Body Weight Considerations	247
Factors That Can Affect Acute Tests	249
Number, Size, and Sex of Dosage Groups	249
References	252
 Chapter 12 Genotoxicity	255
Introduction	255
DNA Structure.....	255
Transcription.....	257
Translation	257
Gene Regulation	257
DNA Repair	258
Excision Repair	258
Error-Prone Repair	258
Mismatch Repair	259
The Adaptive Repair Pathway	259
Plasmids.....	259
Plasmids and DNA Repair.....	260
Nature of Point Mutations	260
Suppressor Mutations	262

Adduct Formation.....	262
Mutations Due to Insertion Sequences.....	263
The Link between Mutation and Cancer.....	263
Genotoxic versus Nongenotoxic Mechanisms of Carcinogenesis.....	264
Genetic Damage and Heritable Defects.....	264
Reproductive Effects.....	265
Cytogenetics.....	266
Cytogenetic Damage and Its Consequences.....	266
Individual Chromosome Damage.....	266
Chromosome Set Damage.....	267
Test Systems.....	268
ISO Test Profile.....	270
ICH Test Profile.....	270
<i>In Vitro</i> Test Systems.....	270
<i>In Vitro</i> Metabolic Activation.....	270
Cell-Free versus Cell-Based Systems.....	271
Inducing Agents.....	271
Standard Method of S9 Fraction Preparation.....	272
S9 Mix.....	272
Bacterial Mutation Tests.....	273
Reversion Tests: Background.....	274
Genetic Makeup of Tester Strains.....	274
Use of the Plasmid pKM101.....	274
<i>Escherichia coli</i> Tester Strains.....	274
Storage and Checking of Tester Strains.....	275
Plate Incorporation Assay.....	275
Protocol for Dose Ranging and Selection.....	275
Controls.....	277
Evaluation of Results.....	278
Eukaryotic Mutation Tests.....	280
<i>In Vitro</i> Tests for the Detection of Mammalian Mutation.....	281
<i>In Vivo</i> Mammalian Mutation Tests.....	288
<i>In Vitro</i> Cytogenetic Assays.....	289
Cell Types.....	290
Chinese Hamster Cell Lines.....	290
Human Peripheral Blood Lymphocytes.....	290
Positive and Negative Controls.....	290
Treatment of Cells.....	291
Scoring Procedures.....	292
Data Recording.....	292
Presentation of Results.....	292
<i>In Vitro</i> Cytogenetics Assays.....	293
Somatic Cell Assays.....	293
Germ Cell Assays.....	293
Heritable Chromosome Assays.....	294
Germ Cell Cytogenetic Assays.....	294
Sister Chromatid Exchange Assays.....	294
Relevance of SCE in Terms of Genotoxicity.....	294
Experimental Design.....	295
References.....	296

Chapter 13	Subchronic and Chronic Toxicity and Reproductive and Developmental Toxicity	305
	Introduction	305
	Objectives	305
	Regulatory Considerations	306
	Good Laboratory Practices	306
	Animal Welfare Act	306
	Regulatory Requirements for Study Design.....	306
	Study Design and Conduct.....	307
	Animals.....	307
	Setting Doses	307
	Parameters to Measure	308
	Body Weight	308
	Food Consumption	308
	Clinical Signs.....	308
	Clinical Pathology	309
	Histopathology	310
	Study Interpretation and Reporting	314
	Reproductive and Developmental Toxicity	315
	Introduction	315
	ICH Study Designs.....	315
	Male and Female Fertility and Early Embryonic Development	
	to Implantation	316
	Embryo-Fetal Development	317
	Pre- and Postnatal Development	317
	Single-Study and Two-Study Designs for Rodents	318
	Dose and Sample Preparation.....	319
	Methodological Issues.....	319
	Control of Bias	319
	Diet	319
	Gravid Uterine Weights	320
	Implant Counts and Determination of Pregnancy	320
	Fetal Examinations	321
	Examination of External Genitalia	321
	Visceral Fetal Examinations	322
	Skeletal Fetal Examination.....	322
	Developmental Signs.....	323
	Behavioral Tests.....	323
	Detecting Effects on Male Reproduction	324
	Data Interpretation.....	324
	Use of Statistical Analyses	324
	Associations between Developmental and Maternal Toxicity	326
	<i>In Vitro</i> Alternatives.....	327
	References	329
Chapter 14	Carcinogenicity	333
	Animal Model	333
	Dose Selection.....	335
	Number of Dose Levels	335
	Group Size	335
	Route of Administration	335